Appropriate use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for atherosclerotic cardiovascular disease: Comparison of recommendations from different guidelines or consensus around the world
Jia Ling Lin, Po Hsun Huang, Hung I. Yeh, Yi Heng Li*
*此作品的通信作者
研究成果: Review article › 同行評審
5
引文
斯高帕斯（Scopus）